Stockreport

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab [Yahoo! Finance]

HOOKIPA Pharma Inc.  (HOOK) 
Last hookipa pharma inc. earnings: 3/19 07:00 am Check Earnings Report
PDF HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from approximately 40 patients treated with HB-200 in combination with pembrolizuma [Read more]